Conditions: Healthy
Keywords: rifampin pharmacokinetics PF-06463922 drug interaction
Allocation:  | Intervention model: CROSSOVER
Enrollment: 12
Healthy volunteers: yes

Brief summary:
The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

Detailed description:
This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study in approximately 12 healthy subjects employing administration of a single oral dose of PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.

Arms:
arm 1: subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.

Interventions: intervention 1: PF-06463922 intervention 2: rifampin
Intervention descriptions: intervention 1: 100 mg oral dose on day 1 in period 1 and on day 8 in period 2 intervention 2: 600 mg QD from day 1 to day 12 in period 2.

Protocol document: